FDA Approves Ultragenyx Gene Therapy Fayuvi for Sanfilippo Type A
FDA approval of Fayuvi provides the first disease-specific option for Sanfilippo type A based on biomarker and developmental endpoints from early-phase trials. Observational natural history controls limit causal certainty, and long-term functional outcomes require further study. Broader newborn screening and pricing decisions will determine population-level impact.
Next steps include a required post-marketing confirmatory trial and potential label expansion to presymptomatic infants identified via newborn screening pilots. Comparative data against emerging substrate reduction or small-molecule approaches will clarify positioning within the treatment armamentarium.
Ultragenyx: Phase 3 confirmatory trial will report stabilized Vineland scores in at least 60% of treated patients at 36 months by Q4 2028.
Sources (2)
- [1]Primary Source(https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-sanfilippo-syndrome-type)
- [2]Supporting Source(https://www.nejm.org/doi/full/10.1056/NEJMoa2301234)